Action TCRX TSCAN THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues TScan Therapeutics, Inc.

Actions

TCRX

US89854M1018

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 23/04/2024 		Varia. 5j. Varia. 1 janv.
7,26 USD +1,97 % Graphique intraday de TScan Therapeutics, Inc. +1,82 % +24,53 %
16/04 TScan Therapeutics, Inc. fait le point sur son portefeuille de produits cliniques et souligne ses priorités à court terme CI
08/04 TScan Therapeutics, Inc. annonce des changements au sein de sa direction CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
TScan Therapeutics Announces Closing of Upsized Public Offering
TScan Therapeutics Closes $150.1 Million Securities Offering
TScan Therapeutics Announces Closing of Upsized Public Offering
TScan Therapeutics Prices $150.1 Million Public Offering of Shares, Warrants
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
TScan Therapeutics Launches $125 Million Securities Offering; Shares Rise After Hours
TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
TScan Therapeutics, Inc. Provides Clinical Pipeline Update and Highlights Near-Term Priorities
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
TScan Therapeutics, Inc. Announces Executive Changes
TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference
TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference
TScan Therapeutics Files $300 Million Mixed-Securities Shelf
TScan Therapeutics Q4 Net Loss Narrows, Revenue Increases
TScan Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
TScan Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action TCRX
  4. Actualités TScan Therapeutics, Inc.
  5. Autres langues